50 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
High-Potency Phenylquinoxalinone Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Activators.
University of California
Nanomolar-Potency Aminophenyl-1,3,5-triazine Activators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel for Prosecretory Therapy of Dry Eye Diseases.
University of California
Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.
Istituto Giannina Gaslini
¿F508-CFTR correctors: synthesis and evaluation of thiazole-tethered imidazolones, oxazoles, oxadiazoles, and thiadiazoles.
Wuhan University of Science and Technology
Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator.
Vertex Pharmaceuticals
A new 9-alkyladenine-cyclic methylglyoxal diadduct activates wt- and F508del-cystic fibrosis transmembrane conductance regulator (CFTR) in vitro and in vivo.
Universit£
ABSOLUTE CONFIGURATION AND BIOLOGICAL PROPERTIES OF ENANTIOMERS OF CFTR INHIBITOR BPO-27.
University of California
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
University of Oxford
Potent, metabolically stable benzopyrimido-pyrrolo-oxazine-dione (BPO) CFTR inhibitors for polycystic kidney disease.
University of California
An expeditious access to 5-pyrimidinol derivatives from cyclic methylglyoxal diadducts, formation of argpyrimidines under physiological conditions and discovery of new CFTR inhibitors.
University Joseph Fourier-Grenoble 1/Cnrs
Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model.
University of California
Thiazolidinone CFTR inhibitors with improved water solubility identified by structure-activity analysis.
University of California
Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains.
St. Jude Children'S Research Hospital
Novel Substituted Cyclopropyl Compounds as CFTR Modulators for Treating Cystic Fibrosis.
Smith, Gambrell & Russell
Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis.
Abbvie
Discovery of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase CFTR mediated chloride transport.
Genzyme
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities.
Central South University
Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease.
Novartis Institutes For Biomedical Research
Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels.
Université
In silico drug repositioning on F508del-CFTR: A proof-of-concept study on the AIFA library.
National Research Council (Itb-Cnr)
Discovery of GLPG2451, a Novel Once Daily Potentiator for the Treatment of Cystic Fibrosis.
Galapagos
Targeting different binding sites in the CFTR structures allows to synergistically potentiate channel activity.
Universit£
Identification, Structure-Activity Relationship, and Biological Characterization of 2,3,4,5-Tetrahydro-1
D3-Pharmachemistry
Discovery of novel VX-809 hybrid derivatives as F508del-CFTR correctors by molecular modeling, chemical synthesis and biological assays.
University of Genoa
Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis.
Rccs Istituto Giannina Gaslini
Targeting the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein for the Treatment of Cystic Fibrosis.
Therachem Research Medilab (India)
Synthesis and biological activity of structurally diverse phthalazine derivatives: A systematic review.
Y. B. Chavan College of Pharmacy
Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis.
Abbvie
Novel Hits in the Correction of ?F508-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein: Synthesis, Pharmacological, and ADME Evaluation of Tetrahydropyrido[4,3-d]pyrimidines for the Potential Treatment of Cystic Fibrosis.
Siena Biotech
Constrained bithiazoles: small molecule correctors of defective ?F508-CFTR protein trafficking.
University of California
Click-based synthesis of triazolobithiazole ?F508-CFTR correctors for cystic fibrosis.
University of California Davis
Structure-activity relationships of cyanoquinolines with corrector-potentiator activity in ?F508 cystic fibrosis transmembrane conductance regulator protein.
University of California Davis
Fluorinated ?F508-CFTR correctors and potentiators for PET imaging.
University of California Davis
Pyrazolylthiazole as DeltaF508-cystic fibrosis transmembrane conductance regulator correctors with improved hydrophilicity compared to bithiazoles.
University of California Davis
4'-Methyl-4,5'-bithiazole-based correctors of defective delta F508-CFTR cellular processing.
University of California
Asperidines A-C, pyrrolidine and piperidine derivatives from the soil-derived fungus Aspergillus sclerotiorum PSU-RSPG178.
Prince of Songkla University
Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein.
Usona Institute
Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools.
University of Genoa
N-[3H]methylscopolamine labeling of non-M1, non-M2 muscarinic receptor binding sites in rat brain.
University of California
Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity.
Methylgene
Design and Synthesis of Classical and Nonclassical 6-Arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as Antifolates.
Duquesne University